Skip to main content

28 - References

References

692 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 6 References

  1. Katona C, et al. Impact of screening old people with physical illness for depression? Lancet 2000; 356:91–92.
  2. Lyketsos CG. Depression and diabetes: more on what the relationship might be. Am J Psychiatry 2010; 167:496–497.
  3. Gallo JJ, et al. Long term effect of depression care management on mortality in older adults: follow-­up of cluster randomized clinical trial in primary care. BMJ 2013; 346:f2570.
  4. Naghavi M. Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. BMJ 2019; 364:l94.
  5. Ryan J, et al. Late-­life depression and mortality: influence of gender and antidepressant use. Br J Psychiatry 2008; 192:12–18.
  6. Gutsmiedl K, et al. How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-­ group meta-­analysis. BMC Psychiatry 2020; 20:102.
  7. Cipriani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-­analysis. Lancet 2018; 391:1357–1366.
  8. Paykel ES, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25:1171–1180.
  9. Iosifescu DV, et  al. Brain white-­matter hyperintensities and treatment outcome in major depressive disorder. Br J Psychiatry 2006; 188:180–185.
  10. Brown PJ, et  al. Biological age, not chronological age, is associated with late-­life depression. J Gerontol A Biol Sci Med Sci 2018; 73:1370–1376.
  11. Tunvirachaisakul C, et al. Predictors of treatment outcome in depression in later life: a systematic review and meta-­analysis. J Affect Disord 2018; 227:164–182.
  12. Zilcha-­Mano S, et al. Early symptom trajectories as predictors of treatment outcome for citalopram versus placebo. Am J Geriatr Psychiatry 2017; 25:654–661.
  13. Mulsant BH, et al. What is the optimal duration of a short-­term antidepressant trial when treating geriatric depression? J Clin Psychopharmacol 2006; 26:113–120.
  14. Mottram P, et al. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006; 1:CD003491.
  15. Hsu CW, et al. Comparative effectiveness of antidepressants on geriatric depression: real-­world evidence from a population-­based study. J Affect Disord 2022; 296:609–615.
  16. National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE Guideline [NG222]. 2022 (last accessed December 2023); https://www.nice.org.uk/guidance/ng222.
  17. Lenze EJ, et al. Antidepressant augmentation versus switch in treatment-­resistant geriatric depression. N Engl J Med 2023; 388:1067–1079.
  18. Krause M, et al. Efficacy and tolerability of pharmacological and non-­pharmacological interventions in older patients with major depressive disorder: a systematic review, pairwise and network meta-­analysis. Eur Neuropsychopharmacol 2019; 29:1003–1022.
  19. Flint AJ, et al. Recurrence of first-­episode geriatric depression after discontinuation of maintenance antidepressants. Am J Psychiatry 1999; 156:943–945.
  20. Reynolds CF, III, et al. Maintenance treatment of major depression in old age. N Engl J Med 2006; 354:1130–1138.
  21. Horowitz MA, et al. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. BJPsych Advances 2022; 28:297–311.
  22. Romdhani A, et al. Discontinuation of antidepressants in older adults: a literature review. Ther Clin Risk Manag 2023; 19:291–299.
  23. Smoller JW, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women’s Health Initiative study. Arch Intern Med 2009; 169:2128–2139.
  24. Laporte S, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-­analysis of observational studies. Pharmacol Res 2017; 118:19–32.
  25. Ön BI, et al. Antidepressant use and stroke or mortality risk in the elderly. Eur J Neurol 2022; 29:469–477.
  26. Coupland C, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011; 343:d4551.
  27. Haddad YK, et al. A comparative analysis of selective serotonin reuptake inhibitors and fall risk in older adults. J Am Geriatr Soc 2022; 70:1450–1460.
  28. Williams LJ, et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 2008; 23:84–87.
  29. Power C, et al. Bones of contention: a comprehensive literature review of non-­SSRI antidepressant use and bone health. J Geriatr Psychiatry Neurol 2019; 33:340–352.
  30. Fagiolini A, et al. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs 2012; 26:1033–1049.
  31. Fagiolini A, et al. Trazodone in the management of major depression among elderly patients with dementia: a narrative review and clinical insights. Neuropsychiatr Dis Treat 2023; 19:2817–2831.
  32. Heun R, et al. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-­controlled study. J Clin Psychiatry 2013; 74:587–594.
  33. Laux G. The antidepressant efficacy of agomelatine in daily practice: Results of the non-­interventional study VIVALDI. Eur Psychiatry 2011; 26 Suppl 1:647.
  34. Katona C, et al. A randomized, double-­blind, placebo-­controlled, duloxetine-­referenced, fixed-­dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012; 27:215–223.
  35. Bae JH, et al. Systematic review and meta-­analysis of omega-­3-­fatty acids in elderly patients with depression. Nutr Res 2018; 50:1–9.
  36. Hsu TW, et al. The efficacy and tolerability of memantine for depressive symptoms in major mental diseases: a systematic review and updated meta-­analysis of double-­blind randomized controlled trials. J Affect Disord 2022; 306:182–189.

Prescribing in older people CHAPTER 6 37. Smith KR, et al. Methylphenidate use in geriatric depression: a systematic review. Int J Geriatr Psychiatry 2021; 36:1304–1312. 38. Ochs-­Ross R, et al. Comparison of long-­term efficacy and safety of esketamine nasal spray plus oral antidepressant in younger versus older patients with treatment-­resistant depression: post-­hoc analysis of SUSTAIN-­2, a long-­term open-­label phase 3 safety and efficacy study. Am J Geriatr Psychiatry 2022; 30:541–556. 39. Subramanian S, et al. Ketamine for depression in older adults. Am J Geriatr Psychiatry 2021; 29:914–916. 40. Moraros J, et al. The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: a systematic review and meta-­analysis. Depress Anxiety 2017; 34:217–226. 41. Leng Y, et al. Antidepressant use and cognitive outcomes in very old women. J Gerontol A Biol Sci Med Sci 2018; 73:1390–1395. 42. Chan JYC, et al. Depression and antidepressants as potential risk factors in dementia: a systematic review and meta-­analysis of 18 longitudinal studies. J Am Med Dir Assoc 2019; 20:279–286.e271. 43. Carriere I, et al. Antidepressant use and cognitive decline in community-­dwelling elderly people – the Three-­City Cohort. BMC Med 2017; 15:81. 44. Wang YC, et al. Increased risk of dementia in patients with antidepressants: a meta-­analysis of observational studies. Behav Neurol 2018; 2018:5315098. 45. Watt JA, et al. Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-­analysis. BMJ 2021; 372:n532. 46. Jeong HW, et al. Vortioxetine treatment for depression in Alzheimer’s disease: a randomized, double-­blind, placebo-­controlled study. Clin Psychopharmacol Neurosci 2022; 20:311–319. 47. Leong C. Antidepressants for depression in patients with dementia: a review of the literature. Consult Pharm 2014; 29:254–263. 48. Costello H, et al. Antidepressant medications in dementia: evidence and potential mechanisms of treatment-­resistance. Psychol Med 2023; 53:654–667. 49. Jin B, et al. Comparative efficacy and acceptability of treatments for depressive symptoms in cognitive impairment: a systematic review and Bayesian network meta-­analysis. Front Aging Neurosci 2022; 14:1037414. 50. Draper B, et al. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging 2008; 25:501–519. 51. Bose A, et al. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry 2008; 16:14–20. 52. Deidda A, et al. Interstitial lung disease induced by fluoxetine: systematic review of literature and analysis of Vigiaccess, Eudravigilance and a national pharmacovigilance database. Pharmacol Res 2017; 120:294–301. 53. Rosenberg T, et al. The relationship of SSRI and SNRI usage with interstitial lung disease and bronchiectasis in an elderly population: a case-­ control study. Clin Interv Aging 2017; 12:1977–1984. 54. Raskin J, et al. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol 2008; 28:32–38. 55. Johnson EM, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-­life depression. Am J Geriatr Psychiatry 2006; 14:796–802. 56. Gonçalo AMG, et al. The effects of trazodone on human cognition: a systematic review. Eur J Clin Pharmacol 2021; 77:1623–1637.

No comments to display

Back to top